Abstract
The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.
| Original language | English (US) |
|---|---|
| Title of host publication | Annals of the New York Academy of Sciences |
| Publisher | Blackwell Publishing Inc. |
| Pages | 357-367 |
| Number of pages | 11 |
| ISBN (Print) | 1573317012, 9781573317016 |
| DOIs | |
| State | Published - Jan 1 2007 |
| Externally published | Yes |
Publication series
| Name | Annals of the New York Academy of Sciences |
|---|---|
| Volume | 1112 |
| ISSN (Print) | 0077-8923 |
| ISSN (Electronic) | 1749-6632 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
- Biochemistry, Genetics and Molecular Biology(all)
- History and Philosophy of Science
Cite this
}
Thymalfasin for the treatment of chronic hepatitis C infection. / Rustgi, Vinod.
Annals of the New York Academy of Sciences. Blackwell Publishing Inc., 2007. p. 357-367 (Annals of the New York Academy of Sciences; Vol. 1112).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
TY - GEN
T1 - Thymalfasin for the treatment of chronic hepatitis C infection
AU - Rustgi, Vinod
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.
AB - The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.
UR - http://www.scopus.com/inward/record.url?scp=35348980090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35348980090&partnerID=8YFLogxK
U2 - 10.1196/annals.1415.034
DO - 10.1196/annals.1415.034
M3 - Conference contribution
SN - 1573317012
SN - 9781573317016
T3 - Annals of the New York Academy of Sciences
SP - 357
EP - 367
BT - Annals of the New York Academy of Sciences
PB - Blackwell Publishing Inc.
ER -